Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment

Article Page

Abstract

Hypertension (HTN) is a common disease state associated with extensive morbidity and mortality worldwide. It is often difficult for patients with HTN to achieve and maintain a goal blood pressure (BP), despite there being many effective treatment options available. Sacubitril/valsartan is a first-inclass angiotensin receptor neprilysin inhibitor (ARNI) that has garnered approval by the US Food and Drug Administration and the European Medicines Agency as a first-line treatment for heart failure with reduced ejection fraction. During clinical trials for heart failure as well as in independent trials for HTN, sacubitril/valsartan has demonstrated safety and efficacy when it comes to BP lowering, making it a promising antihypertensive agent. Most trials of sacubitril/valsartan were 8 to 12 weeks in length and demonstrated a clinically relevant BP lowering that was frequently more significant than its comparators. While more data are needed to confirm its role as an antihypertensive agent, the data available are promising and it is anticipated that sacubitril/valsartan will gain an indication of HTN.

Keywords: angiotensin receptor blockers, hypertension, neprilysin inhibitor.

Citation: Anderson SL, Marrs JC. Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment. Drugs in Context 2018; 7: 212542. DOI: 10.7573/dic.212542

Disclosure and potential conflicts of interest: The authors do not have any conflicts of interest to disclose. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at https://www.drugsincontext.com/wp-content/uploads/2018/07/dic.212542-COI.pdf

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2018 Anderson SL, Marrs JC. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2018 Anderson SL, Marrs JC. https://doi.org/10.7573/dic.212542. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/sacubitril-valsartan-evaluation-of-safety-and-efficacy-as-an-antihypertensive-treatment

Correspondence: Joel C Marrs, Mail Stop C238, 12850 E. Montview Blvd., Room V20-2128, Aurora, Colorado, USA, 80045. Joel.Marrs@ucdenver.edu

Provenance: invited; externally peer reviewed.

Submitted: 30 May 2018; Peer review comments to author: 5 July 2018; Revised manuscript received: 13 July 2018; Accepted: 13 July 2018; Publication date: 6 August 2018.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252772009.

For all manuscript and submissions enquiries, contact the Editorial office dic.editorial@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF